Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C

Annals of Gastroenterology

Volumn 29, Issue 3, 2016, Pages 282-296

  Manolakopoulos, Spilios ^a   Zacharakis, George ^b,c   Zissis, Miltiadis ^d   Giannakopoulos, Vassilis ^d  

^a HIPPOKRATION HOSPITAL   (Greece)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Chronic hepatitis C; Daclatasvir; Treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ASUNAPREVIR; BENZODIAZEPINE DERIVATIVE; BOCEPREVIR; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CORTICOSTEROID; DABIGATRAN ETEXILATE; DACLATASVIR; DEXAMETHASONE; DIGOXIN; EFAVIRENZ; ETRAVIRINE; INTEGRASE INHIBITOR; LEDIPASVIR; NAFCILLIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; UNINDEXED DRUG;

ALOPECIA; ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BRADYCARDIA; CHILD PUGH SCORE; CHRONIC HEPATITIS C; COUGHING; CREATININE CLEARANCE; DECOMPENSATED LIVER CIRRHOSIS; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEADACHE; HEART ARREST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; LIMIT OF DETECTION; LIVER TRANSPLANTATION; MYALGIA; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENT DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT WITHDRAWAL;

EID: 84976524771     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: 10.20524/aog.2016.0041     Document Type: Review

References (79)

1. Pfaender S, Cavalleri JM, Walter S, et al. Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses. Hepatology 2015;61:447-459.
2. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59:318-327.
3. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87.
4. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-364.
5. Alter MJ. HCV routes of transmission: what goes around comes around. Semin Liver Dis 2011;31:340-346.
6. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
7. Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. J Viral Hepat 2015;22:409-415.
8. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014;61:373-395.
9. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-1359.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
11. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420.
12. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
13. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
14. Ashfaq UA, Javed T, Rehman S, et al. An overview of HCV molecular biology, replication and immune responses. Virol J 2011;8:161.
15. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59:434-441.
16. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-413.
17. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-426.
18. Pawlotsky JM. Hepatitis C virus: standard-of-care treatment. Adv Pharmacol 2013;67:169-215.
19. Lawitz E, Mangia A, Wyles D, et al. SOF for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
20. Degasperi E, Aghemo A, Colombo M. Daclatasvir for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2015;16:2679-88.
21. Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; Apr 18. doi: 10.1111/apt.13633.
22. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236.
23. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879.
24. Raedler LA. Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a new oral combination for the treament of patients with genotype 1 chronic hepatitis C infection. Am Health Drug Benefits 2015;8:54-58.
25. Deeks ED. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: a review in chronic HCV genotype 1 infection. Drugs 2015;75:1027-1038.
26. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1-13.
27. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1075-1086.
28. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1087-1097.
29. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211.
30. Chayama K, Suzuki F, Suzuki Y, et al. All-oral dual combination of daclatasvir plus asunaprevir compared with telaprevir plus peginterferon alfa/ribavirin in treatment-naive Japanese patients chronically infected with HCV genotype 1b: Results from a phase 3 study. Hepatology 2014;60(4 Suppl):1135A.
31. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-749.
32. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008;4:e1000032.
33. Appel N, Zayas M, Miller S, et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 2008;4:e1000035.
34. Neddermann P, Quintavalle M, Di Pietro C, et al. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol 2004;78:13306-13314.
35. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013;19:837-849.
36. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100.
37. Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 2013;110:3991-3996.
38. Pelosi LA, Voss S, Liu M. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 2012;56:5230-5239.
39. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013;18:931-940.
40. Ratziu V, Gadano A, Pol S, et al. Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa-2a and ribavirin in HCV-infected prior null and partial responders: 12-week results of phase 2b COMMAND-2 trial. J Hepatol 2012;56(Suppl 2):S478-S479.
41. El-Sherif O, Back D. Drug interactions of hepatitis c directacting antivirals in the HIV-infected person. Curr HIV/AIDS Rep 2015;12:336-343.
42. Garimella T, Wang R, Luo WL, et al. Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob Agents Chemother 2015;59:5503-5510.
43. Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 patients: phase 2b COMMAND-1 SVR 12 results. Hepatology 2012;56:553A.
44. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012;12:671-677.
45. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus SOF for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
46. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT) 3: ALLY-3 phase 3 study. Hepatology 2015;61:1127-1135.
47. Landis C, Nelson DR Sulkowski M, et al. An integrated safety analysis of SOF+DCV with or without ribavirin in patients with chronic HCV infection. Hepatology 2015;62(Suppl 1):565A.
48. Swallow E, Song J, Yuan Y, et al. Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. J Comp Eff Res 2016;5:129-139.
49. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis c virus nonstructural protein 5a replication complex inhibitor bms-790052 in humans: In vitro and in vivo correlations. Hepatology 2011;54:1924-1935.
50. Wang C, Sun JH, O’Boyle DR, et al. Persistence of resistant variants in hepatitis c virus-infected patients treated with the NS5a replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 2013;57:2054-2065.
51. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis c virus NS5a inhibitor bms-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010;54:3641-3650.
52. Poveda E, Wyles DL, Mena A, Pedreira JD, Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct‐acting antiviral agents. Antiviral Res 2014;108:181-191.
53. Lemm JA, O’Boyle D, Liu M, et al. Identification of hepatitis c virus NS5a inhibitors. J Virol 2010;84:482-491.
54. Kohler JJ, Nettles JH, Amblard F, et al. Approaches to hepatitis c treatment and cure using NS5a inhibitors. Infect Drug Resist 2014;7:41-56.
55. Lim PJ, Gallay PA. Hepatitis c NS5a protein: Two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol 2014;8C:30-37.
56. Jensen DM, Kenneth E. Sherman, Hezode C. et al on behalf of the HALLMARK-QUAD Study Team. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol 2015;63:30-37.
57. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. The prevalence and the effect of HCV NS5A resistance-associated variants in patients with compensated cirrhosis treated with Ledipasvir/SOF ± RBV. J Hepatol 2015;62(Suppl 2):Abstract PO773.
58. Kwo P, Gane E, Peng C-Y, et al. Efficacy and safety of grazoprevir/ elbasvir +/− RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial. J Hepatol 2015;62(Suppl 2):Abstract P0886.
59. Drory Sobol H, Wyles D, Ouyang W, et al. Long term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol 2015;62(Suppl 2):Abstract O059.
60. Jacobson I, Zeuzem S, Flisiak R. Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naïve patients with HCV genotype 1: phase 3 COMMAND-3 results (abstract no. 0213). J Viral Hepat 2014;21(Suppl S2):7-8.
61. Hezode C, Alric L, Brown A, et al. Randomized controlled trial of the NS5A inhibitor plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther 2015. Aug 27. doi: 10.3851/IMP2985. [Epub ahead of print]
62. Dore GJ, Lawitz E, Hezode C, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 2015;148:355-366.
63. Asselah T. Daclatasvir plus SOF for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol 2014;61:435-438.
64. Bourliere M. Treatment of patients with decompensated liver cirrhosis: who benefits, who deteriorates, where is the point of no return? J Viral Hepat 2015;22(Suppl S3):O132.
65. Poordad F, Schiff ER, Vierling JM, et al. Phase III Daclatasvir, SOF, and Ribavirin combination for HCV patients with advanced cirrhosis or post-liver transplant recurrence (ALLY 1). J Hepatol 2015;62(Suppl 2):S261-S262. Abstract L08.
66. Deterding K, Hner Zu Siederdissen C, Port K, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 2015;42:889-901.
67. Foster GR, McLauchlan J, Irving W, et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks SOF and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol 2015;62(Suppl 2):S190-S191. Abstract O002.
68. Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of the combination daclatasvir-SOF in HCV genotype 1-mono-infected patients from the French observational cohort ANRS CO22 HEPATHER. J Hepatol 2015;62(Suppl 2):Abstract LB3.
69. Hezode C, De Ledighen V, Fontaine H, et al. Daclatasvir plus SOF with or without ribavirin in patients with HCV Genotype 3 infection: interim analysis of a French multicenters compansionnate use program. J Hepatol 2015;62(Suppl 2): Abstract LP05.
70. Welzer T, Petersen J, Ferenci P, et al. Efficacy and safety of Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a compassionate use program. Hepatology 2015;62 (Suppl 1):225A. Abstract 37.
71. US National Institutes of Health. ClinicalTrials.gov 2015. https://clinicaltrials.gov/ct2/show/NCT02262728. First received 6 Oct 2014.
72. Charlton M, Everson T, Flamm SL, et al. Ledipasvir and SOF plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
73. Coilly A, Fougerou C, De Ledinghen V, et al. The association of SOF and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: results from a large French prospective multicentric ANRS CO23 cupilt cohort. J Hepatol 2015;62(Suppl 2):Abstract G15.
74. Herzer K Welzel T, Ference P, et al. Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HVB recurrence: interim results of a multicenter compassionate use program. Hepatology 2015;62(Suppl 1):341A.
75. Leroy V, Dumortier J, Coilly A, et al. Efficacy of SOF and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015;13:1993-2001.
76. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat 2011;18:745-759.
77. Leroy V, Augus PW, Bronowicki T-P, et al. All-oral treatment with Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 weeks in HCV genotype 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study. Hepatology 2015;62(Suppl 1): Abstract LB-3.
78. Fontaine H, Lacombe K, Dhiver C, et al. Daclatasvir plus SOF with or without ribavirin in patients with HIV-HCV coinfection: interim analysis of a french multicenter compassionate use program. J Hepatol 2015;62(Suppl 2): Abstract LP23.
79. Wyles DL Ruane P, Sulkowski MS, et al. Daclatsvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015;373:714-725.